Follow
norman putzki
norman putzki
Unknown affiliation
Verified email at uni-due.de
Title
Cited by
Cited by
Year
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
F Lublin, DH Miller, MS Freedman, BAC Cree, JS Wolinsky, H Weiner, ...
The Lancet 387 (10023), 1075-1084, 2016
4802016
Trial of fingolimod versus interferon beta-1a in pediatric multiple sclerosis
T Chitnis, DL Arnold, B Banwell, W Brück, A Ghezzi, G Giovannoni, ...
New England Journal of Medicine 379 (11), 1017-1027, 2018
3192018
First clinical study on ultra-high-field MR imaging in patients with multiple sclerosis: comparison of 1.5 T and 7T
K Kollia, S Maderwald, N Putzki, M Schlamann, JM Theysohn, O Kraff, ...
American Journal of Neuroradiology 30 (4), 699-702, 2009
2292009
Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management
AM Arvin, JS Wolinsky, L Kappos, MI Morris, AT Reder, C Tornatore, ...
JAMA neurology 72 (1), 31-39, 2015
1892015
CD4+ CD25+ FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis
M Kumar, N Putzki, V Limmroth, R Remus, M Lindemann, D Knop, ...
Journal of neuroimmunology 180 (1-2), 178-184, 2006
1852006
Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS
J Hobart, AR Blight, A Goodman, F Lynn, N Putzki
Neurology 80 (16), 1509-1517, 2013
1802013
Prevalence of migraine, tension‐type headache and trigeminal neuralgia in multiple sclerosis
N Putzki, A Pfriem, V Limmroth, Ö Yaldizli, B Tettenborn, HC Diener, ...
European Journal of Neurology 16 (2), 262-267, 2009
1662009
Quality of life in 1000 patients with early relapsing–remitting multiple sclerosis
N Putzki, J Fischer, K Gottwald, G Reifschneider, S Ries, A Siever, ...
European journal of neurology 16 (6), 713-720, 2009
1052009
Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells
N Putzki, MK Baranwal, B Tettenborn, V Limmroth, E Kreuzfelder
European neurology 63 (5), 311-317, 2010
1022010
Kinesthesia is impaired in focal dystonia
N Putzki, P Stude, J Konczak, K Graf, HC Diener, M Maschke
Movement disorders 21 (6), 754-760, 2006
1012006
Efficacy of natalizumab in second line therapy of relapsing–remitting multiple sclerosis: results from a multi‐center study in German speaking countries
N Putzki, O Yaldizli, M Mäurer, S Cursiefen, S Kuckert, C Klawe, ...
European journal of neurology 17 (1), 31-37, 2010
1002010
Quality Assessment in Multiple Sclerosis Therapy (QUASIMS) A comparison of interferon beta therapies for relapsing-remitting multiple sclerosis
V Limmroth, R Malessa, UK Zettl, J Koehler, G Japp, P Haller, W Elias, ...
Journal of neurology 254, 67-77, 2007
872007
Prevalence and severity of multiple-sclerosis-associated fatigue in treated and untreated patients
N Putzki, Z Katsarava, S Vago, HC Diener, V Limmroth
European Neurology 59 (3-4), 136-142, 2008
782008
Corpus callosum index and long-term disability in multiple sclerosis patients
Ö Yaldizli, R Atefy, A Gass, D Sturm, S Glassl, B Tettenborn, N Putzki
Journal of neurology 257, 1256-1264, 2010
752010
Natalizumab reduces clinical and MRI activity in multiple sclerosis patients with high disease activity: results from a multicenter study in Switzerland
N Putzki, Ö Yaldizli, R Bühler, G Schwegler, D Curtius, B Tettenborn
European neurology 63 (2), 101-106, 2010
732010
Multiple sclerosis associated fatigue during natalizumab treatment
N Putzki, Ö Yaldizli, B Tettenborn, HC Diener
Journal of the neurological sciences 285 (1-2), 109-113, 2009
712009
The interferon beta therapies for treatment of relapsing–remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the …
V Limmroth, N Putzki, NJ Kachuck
Therapeutic Advances in Neurological Disorders 4 (5), 281-296, 2011
702011
Fatigue and progression of corpus callosum atrophy in multiple sclerosis
Ö Yaldizli, S Glassl, D Sturm, A Papadopoulou, A Gass, B Tettenborn, ...
Journal of neurology 258, 2199-2205, 2011
642011
Natalizumab is effective as second line therapy in the treatment of relapsing remitting multiple sclerosis
N Putzki, K Kollia, S Woods, E Igwe, HC Diener, V Limmroth
European journal of neurology 16 (3), 424-426, 2009
582009
Relapsing neuromyelitis optica responsive to glatiramer acetate treatment.
K Gartzen, V Limmroth, N Putzki
European Journal of Neurology 14 (6), e12-3, 2007
562007
The system can't perform the operation now. Try again later.
Articles 1–20